Pharmaceutical - Cardio-vascular, Legal

Filter

Current filters:

Cardio-vascularLegal

Popular Filters

Servier to appeal EC fine over perindopril

Servier to appeal EC fine over perindopril

11-07-2014

French privately-held drugmaker Servier has said it will appeal before the European Union Court of Justice…

Cardio-vascularEuropeFinancialLegalPerindoprilperindoprilPharmaceuticalServier

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

02-06-2014

After facing more than 2,000 law suits in the USA, claiming Pradaxa (dabigatran) caused severe or fatal…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceutical

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

13-02-2014

The Australian Competition and Consumer Commission revealed today that is has instituted proceedings…

Asia-PacificAustraliaCardio-vascularLegalLipitorMarkets & MarketingPfizerPharmaceutical

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

AstraZeneca “cooperating” with US DoJ inquiry into Brilinta trial

AstraZeneca “cooperating” with US DoJ inquiry into Brilinta trial

01-11-2013

AstraZeneca said it is cooperating with the US Department of Justice after an investigation has been…

AstraZenecaBrilintaCardio-vascularEuropeLegalPharmaceutical

Novartis under investigation for manipulating data in Japanese clinical trials

Novartis under investigation for manipulating data in Japanese clinical trials

27-09-2013

Swiss drug major Novartis has said it regrets the inconvenience caused by its investigator-initiated…

Asia-PacificCardio-vascularLegalNovartisPharmaceuticalRegulationvalsartan

US Appeals Court reverses 2012 decision on Lovaza, clearing way for generics

13-09-2013

Reversing a district court decision last year (The Pharma Letter May 30, 2012), the US Court of Appeals…

AmarinCardio-vascularGenericsGlaxoSmithKlineLegalLovazaNorth AmericaPar PharmaceuticalsPatentsPharmaceuticalTeva Pharmaceutical IndustriesVascepa

EU Commission focus now on Servier and others re-perindopril antitrust issues

31-07-2012

The European Commission has informed French independent pharmaceutical company Servier and several of…

Cardio-vascularEuropeGenericsLegalMarkets & MarketingMylan LaboratoriesPatentsperindoprilPharmaceuticalServierTeva Pharmaceutical Industries

US court rules in favor of Pronova/GlaxoSmithKline in Lovaza patent dispute

30-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) which has the marketing rights for Lovaza (omega-3-acid ethyl…

Cardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaPatentsPharmaceuticalPronova BioPharmaTeva Pharmaceutical Industries

United Therapeutics sues Sandoz over Remodulin patent infringement

16-03-2012

United Therapeutics (Nasdaq: UTHR) says that it has filed a law suit in the US District Court for the…

Cardio-vascularGenericsLegalNorth AmericaNovartisPatentsPharmaceuticalRemodulinSandozUnited Therapeutics

The Medicines Co settles with APP over Angiomax

24-01-2012

The Medicines Company (Nasdaq: MDCO) says that it has settled the law suits filed by company in the US…

AngiomaxAPP PharmaceuticalsCardio-vascularFresenius KabiGenericsLegalNorth AmericaPatentsPharmaceuticalThe Medicines Company

J&J unit Scios pleads guilty to misbranding Natrecor, paying $85 million fine

07-10-2011

Scios, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), has pleaded guilty tto a misdemeanor…

Cardio-vascularJohnson & JohnsonLegalNatrecorNorth AmericaPharmaceuticalScios

Back to top